Phaseline

Companies › Passage Bio

Passage Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PBFT02
Gene therapy delivering functional GRN gene to the brain
GRNPhase 1Frontotemporal Dementia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04747431PBFT02Phase 1Frontotemporal DementiaNeurologyJun 2026

From the company's SEC filings

Cash and short-term investments of $20m on 2026-09-30; operating cash outflow about $35m a year; runway about 7 months at that burn, to Apr 2027

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GRN (1)

Companies with the same targets

Prevail Therapeutics AviadoBio Voyager Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.